Monday, March 24, 2014


1.JAGSONPAL PHARMACEUTICALS LTD is a 5 rupee face value pharmaceuticals stock which traded at 9.95 only. 
2. Year high/ year low for jagsonpal pharma is 12.70 and 7.00 so when year high and year low ratio is below 2 then we think stock is stable. 
3.Promoters of JAGSONPAL PHARMACEUTICALS LTD hold 65.79% with no any pledged share. 
4. As my rule JAGSONPAL PHARMACEUTICALS LTD is a dividend paying stock which pay 0.25 paisa per share dividend in 2009 and in 2010 to 2013 continue pay 0.50 paisa per share dividend. 
5.When we divide net revenue ( net income not confuse with net profit ) per year with total number of shares we get net revenue per share per year which is 63 in case of JAGSONPAL PHARMACEUTICALS LTD read my book for more detail of this concept. 
6.JAGSONPAL PHARMACEUTICALS LTD have no any bulk or block deal in last 2 year which is another sign of stability.
7. Base price ( last three year avarage price ) for JAGSONPAL PHARMACEUTICALS LTD is 12.16 so if we buy @9.95 then it is 20 % below base price. 
8. I have no any share of JAGSONPAL PHARMACEUTICALS LTD ( but plan to buy in my wife ac)


  1. i want to sell 500. give the target

  2. I want to Invest in JAGSONPAL PHARMACEUTICALS LTD for 2-3 years. Should I invest in this stock. Also Could you suggest me any penny stock for 2-3 years.

    1. please visit my penny share tab of my website for latest recommendations.

  3. I got some valuable points through this blog. Thank you sharing this blog.
    NEC Phones Brisbane


Share Your View in Comment

disclaimer:-Trading in stock market is very risky. This website is not perfect. This is not an advisory service to buy or sell. The contents of “” are only for educational purposes. No liability is accepted for any content in “”. Subject to pindwara(india) jurisdiction only. The author is neither a registered stockbroker nor a registered advisor and does not give investment advice.. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, author of this website is not a trend technical analyst.